D
r. Fink's commentary in this issue of The Journal of ECT might be viewed in light of this pearl of wisdom. We can indeed learn a lot from Ladislas Meduna's contributions to psychiatry, which help us avoiding repeating history: Even if an idea contradicts the dogma of the day, it might be worth pursuing it anyway. Dr. Meduna observed an apparent antagonism between psychotic symptoms and seizures in patients and concluded that seizures might be beneficial for the treatment of psychosis. Today, we know that this observation is not entirely correct but, despite this, it lead to the development of one of the most efficacious treatment modalities in neuropsychiatry. Another less widely known contribution of Dr. Meduna was his discovery of carbon dioxide therapy; he tried treating various neuropsychiatric disorders with a mixture of 70% oxygen and 30% carbon dioxide. 1 This treatment is no longer used today.
What is the difference between the outcomes of these 2 discoveries of Dr. Meduna? Both are based in careful and deliberate study following the classic principles of clinical observation, hypothesis, and experimentation in animals and humans. However, of the 2, only seizure therapy has ultimately found to be efficacious. Dr. Meduna and his many followers were able to establish this fact in an atmosphere nurturing research and accepting shortcomings and failures as temporary setbacks.
Nobody can argue that electroconvulsive therapy (ECT)-certainly in its modified form-is a very effective treatment with an acceptable side effect profile. It is an important treatment modality for those patients most in need of help, those for whom less invasive treatments might be inadequate. It is a moral imperative for us physicians in the field to do everything possible to increase access to its use worldwide. Indeed, it is the explicit mission of the Association for Convulsive Therapy to "to improve the lives of people everywhere affected by neuropsychiatric illness through promotion of excellence in ECT and related central nervous system stimulation treatments." In addition to ensuring access to ECT, this mission includes promoting excellence in the delivery of ECT, which also means continuously improving ECT by setting standards and by lowering the side effect burden. Improving the standards of care will have the added benefit of decreasing the undeserved societal stigma surrounding its use.
Dr. Fink is to be commended for teaching us on the evolution of ideas that led to the current form of convulsive therapy during the last 70 years. However, some of his statements deserve careful consideration. Reputable researchers of the newer brain stimulation methods never did proffer them "as replacements for ECT." To the contrary, most of them are ECT providers themselves. As clinician-researchers, they critically reflect on their work, not only on its scientific but also on its clinical value. 2, 3 In addition, the intention to "salvage a marketable psychiatric use for TMS" was certainly not the driving factor behind the development of magnetic seizure therapy. Rather, it is the desire to salvage convulsive therapy by reducing its side effects that motivates the development of MST. 4 It is inappropriate to criticize research on novel brain stimulation methods on the grounds of supposed economical agendas. Dr. Fink is certainly right in his observation that TMS, MST, and VNS have not convincingly proven to be efficacious yet, but the operative term is 'yet.' Research on the application of these methods in neuropsychiatric disorders has only begun a decade or 2 ago. Time will tell whether these techniques will turn out to be the new ECT or the new carbon dioxide therapy or something in between.
It is fascinating and scientifically important that these methods have been shown to have neurobiological effects on brain systems at different levels; from gene expression to interconnected systems and that some seem to have antidepressant properties. The clinical significance of these results remains to be determined. But regardless of the outcome of this determination, this research might well shed some light on some factors essential to antidepressant response. We are physicians in addition to being researchers; in this chosen role we are committed to help patients afflicted with a deadly disease. How could we possibly disregard data possibly contributing to the knowledge on the neurobiology of this very disease? This knowledge might most certainly contribute to the development of more focused treatments. If Dr. Meduna's early research on seizure therapy had been disregarded because it did not fit the dogma of the day, there simply would be no clinical ECT today.
While being physicians and researchers at the same time we should balance the goals of maintaining access to the most effective treatments available while simultaneously searching for ways to improve the quality of life for patients in our care. These goals are certainly not mutually exclusive, as some might perceive it. It might be, that the concern for the suffering of patients is the most important driving factor leading together with rigorous and critical science to even better treatments in the future. It certainly seems that Dr. Meduna developed his ideas by this very principle of clinical research.
Probably the most important lesson we can learn from Dr. Fink's commentary is that an open mind is essential for progress in clinical medicine. We should not throw out new ideas on putative treatments solely on the basis that they are in an early stage of development. Their value has to be established by science and not opinion. Unlike the patients afflicted with severe and deadly neuropsychiatric disorders, we have nothing to lose by letting results of clinical investigations on novel brain stimulation approaches inform us on their putative clinical value. How can we not take the chance to discover a therapeutic breakthrough for these patients, even if the odds seem low today? Were Dr. Meduna's observations met at the time with widespread criticisms on supposed hidden agendas, ECT would simply not be available today. Our patients need the best treatment, not the best dogma; the best doctors know that.
